Miyachi Hideaki, Konishi Takaaki, Hashimoto Yohei, Matsui Hiroki, Fushimi Kiyohide, Inozume Takashi, Yasunaga Hideo
Department of Dermatology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
J Dermatol. 2023 Feb;50(2):212-221. doi: 10.1111/1346-8138.16641. Epub 2022 Nov 24.
Pemphigus is a life-threatening autoimmune blistering disease. Patient characteristics, treatment courses, and outcomes remain unclear owing to its rarity. To describe the background, treatment, and outcomes of pemphigus, we identified 2598 patients with pemphigus vulgaris and 1186 patients with pemphigus foliaceus from a nationwide inpatient database in Japan. Patients with pemphigus vulgaris were younger (62 vs 72 years, P < 0.001), had fewer comorbidities, and were more likely to be admitted to high-volume hospitals (38% vs 30%, P < 0.001) than those with pemphigus foliaceus. Patients with pemphigus vulgaris had undergone more aggressive treatment, including steroid pulse therapy, intravenous immunoglobulin, or plasmapheresis, compared with those with pemphigus foliaceus (48% vs 42%, P = 0.001); specifically, in patients aged <70 years, the pemphigus vulgaris group was more likely to undergo aggressive treatment than the pemphigus foliaceus group (52% vs 45%), whereas there was no significant difference in patients aged ≥70 years (40% vs 40%). Immunosuppressive agents (30% vs 26%, P = 0.015) and analgesics, including opioids (45% vs 36%, P < 0.001), were used more frequently, whereas topical corticosteroids were used less frequently (32% vs 48%, P < 0.001) in patients with pemphigus vulgaris compared with those with pemphigus foliaceus. In-hospital mortality was lower in patients with pemphigus vulgaris than in those with pemphigus foliaceus (2.2% vs 4.0%, P = 0.002); in the comparison stratified by age, the mortality was equivalent among the two groups (0.6% in patients aged <70 years and 6.1% in those aged ≥70 years). Overall, patients with pemphigus vulgaris had a 10-day longer hospitalization period and higher hospitalization costs than those with pemphigus foliaceus. Our findings provide useful information for understanding the current trends in the management of pemphigus in Japan.
天疱疮是一种危及生命的自身免疫性疱病。由于其罕见性,患者特征、治疗过程及结局仍不明确。为描述天疱疮的背景、治疗及结局,我们从日本全国住院患者数据库中识别出2598例寻常型天疱疮患者和1186例落叶型天疱疮患者。与落叶型天疱疮患者相比,寻常型天疱疮患者更年轻(62岁对72岁,P<0.001),合并症更少,且更有可能入住大型医院(38%对30%,P<0.001)。与落叶型天疱疮患者相比,寻常型天疱疮患者接受了更积极的治疗,包括类固醇冲击疗法、静脉注射免疫球蛋白或血浆置换(48%对42%,P=0.001);具体而言,在年龄<70岁的患者中,寻常型天疱疮组比落叶型天疱疮组更有可能接受积极治疗(52%对45%),而在年龄≥70岁的患者中无显著差异(40%对40%)。与落叶型天疱疮患者相比,寻常型天疱疮患者更频繁使用免疫抑制剂(30%对26%,P=0.015)和包括阿片类药物在内的镇痛药(45%对36%,P<0.001),而外用皮质类固醇的使用频率较低(32%对48%,P<0.001)。寻常型天疱疮患者的住院死亡率低于落叶型天疱疮患者(2.2%对4.0%,P=0.002);在按年龄分层的比较中,两组死亡率相当(年龄<70岁的患者为0.6%,年龄≥70岁的患者为6.1%)。总体而言,寻常型天疱疮患者的住院时间比落叶型天疱疮患者长10天,住院费用更高。我们的研究结果为了解日本天疱疮管理的当前趋势提供了有用信息。